BioStem Technologies (BSEM) reported second-quarter revenue of $7.9 million, a 29% increase from the prior quarter but down 28.2% year-over-year, as the company realigned its commercial strategy toward hospital procedural reimbursement following its August 2024 uplist to the Nasdaq Capital Market.
Hospital revenue rose to $7 million in Q2 from $5.7 million in Q1, while physician office revenue climbed to $1.1 million from $800,000. The company’s reimbursement mix shifted to 87% procedural-based under Medicare’s Diagnosis Related Group framework, down from 100% product-based reimbursement prior to its acquisition-driven transition. Gross margin held steady at 61% sequentially but declined from 94% a year earlier, reflecting the shift in revenue mix.
Full-year 2026 revenue guidance was raised to $26 million–$29 million, up from the prior range of $25 million–$29 million, with management citing stronger hospital adoption of its regenerative tissue products. Adjusted EBITDA loss narrowed to $4.6 million from $5.7 million in Q1, while GAAP net loss totaled $9.0 million, or $0.52 per share. Cash used in operations reached $5.5 million, leaving the company with $7.0 million in cash at quarter-end, down from $13.7 million at the end of Q1.
During the quarter, BioStem closed a $2.5 million private placement with its first institutional investor and resolved $5.3 million in debt through a $3.5 million cash payment and a $1.0 million note exchange. The company also announced plans to bring manufacturing in-house at its Pompano Beach, Florida facility by the first half of 2027, targeting a monthly production capacity of 100,000 square centimeters—four times current utilization.
BioStem’s product portfolio spans three platform technologies—BioRetain, SteriTek, and CryoTek—with over 10 commercial products and more than 1.2 million applications to date. The company holds eight new U.S. design patents covering fenestrated placental allograft technologies. Management highlighted clinical evidence showing improved outcomes in urology and foot-and-ankle procedures, including reduced recovery times and complication rates.
The stock, trading around $3.20 at the time of the report, has declined roughly 49% over the prior six months, with a market capitalization of approximately $56–$57 million on 17.5 million shares outstanding.
